No Data
No Data
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Buy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal Trial
Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate
Express News | Regulus Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $95.9 Mln; Cash Runway Into H1 2026
Regulus Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Jenna Ragan : RIGL!! RIGL!!![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Trytosaveabit OP Jenna Ragan : Hehehe! Yes ma’am pretty lady! I just knew that one would get you attention! Hehehe. Thanks for the smile you just gave me! Hehehe![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Jenna Ragan Trytosaveabit OP : You are very welcome![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Seraphicall : CMMB yes.
but you have these many holdings?
MARKET-TEST-DUMMY : I want to say thank you because it takes time to research this information. Your very kind for sharing.
A true gentleman and scholar!
View more comments...